Omega Therapeutics was founded in 2017 through Flagship Labs, the innovation foundry of Flagship Pioneering. David Berry, M.D., Ph.D., General Partner at Flagship, led the founding team, building on epigenetics research by Richard Young and Rudolf Jaenisch at MIT and the Whitehead Institute. Flagship Pioneering formally unveiled Omega and appointed Mahesh Karande as President and CEO in September 2019. The company's name references the last letter of the Greek alphabet.
The OMEGA Epigenomic Programming platform leverages Insulated Genomic Domains (IGDs) as fundamental gene regulators. IGDs represent naturally occurring units of the human genome that function as self-contained regulatory modules, allowing precise targeting of specific genes without affecting neighboring regions. The company's epigenomic controllers are delivered via lipid nanoparticles (LNPs), targeting specific genes to durably modify their expression through epigenetic mechanisms rather than permanent DNA alterations. The company described the platform as an alternative to gene editing approaches like CRISPR, emphasizing control of gene expression without cutting DNA. Omega published preclinical data in Nature Communications in September 2024.
OTX-2002 represented Omega's most advanced clinical asset—a first-in-class, bicistronic mRNA-encoded epigenomic controller designed to durably downregulate MYC expression via two different epigenetic modifications. MYC plays a significant role in more than 50% of all human cancers, with overexpression associated with aggressive disease progression in up to 70% of hepatocellular carcinoma patients.
The program achieved several regulatory milestones: FDA IND clearance in July 2022, enabling clinical development; FDA Orphan Drug Designation for hepatocellular carcinoma in November 2022; and a clinical supply agreement with Roche for atezolizumab combination study in March 2023. The MYCHELANGELO I Phase 1/2 trial dosed its first patient in November 2022. In November 2024, Omega announced successful completion of the Phase 1 monotherapy dose escalation, enrolling 24 patients across six dose cohorts ranging from 0.02 mg/kg to 0.3 mg/kg. The trial achieved a 50% disease control rate in response-evaluable HCC patients and demonstrated .
Omega priced its initial public offering at $17.00 per share on July 29, 2021, offering 7.4 million shares with Goldman Sachs & Co. LLC and Cowen as joint book-running managers. Gross proceeds totaled approximately $144.6 million including full exercise of the underwriter option, and trading commenced on the Nasdaq Global Select Market under the symbol "OMGA." The IPO valued Omega at approximately $866 million.
On January 4, 2024, Omega announced a research collaboration with Novo Nordisk focused on developing novel therapeutics for obesity management using epigenomic controllers. The partnership leveraged Omega's platform to transition white adipose cells to metabolically active brown adipose cells. This collaboration was one of the first two programs signed under the framework agreement between Flagship Pioneering and Novo Nordisk. The company received $5.1 million upfront, with approximately $21.6 million in cost reimbursement spread through 2027. The bulk of the potential value remained contingent on future milestones and royalties.
By the time of bankruptcy, Omega's market capitalization had declined to $8.03 million—less than 1% of its IPO valuation. Nasdaq notified Omega on February 18, 2025 that its common stock would be delisted due to the bankruptcy filing and associated concerns. Trading was suspended effective February 25, 2025, with shares subsequently moving to over-the-counter markets under the symbol OMGAQ.
Throughout 2024, Omega's financial position weakened, and the company reported losses averaging $16-20 million per quarter while cash reserves declined:
| Quarter | Net Loss | Cash Balance | R&D Expense | Key Events |
|---|
| Q1 2024 | $20.1M | — | $15.4M | 35% workforce reduction |
| Q2 2024 | $16.3M | $45.9M | $12.9M | Cost prioritization |
| Q3 2024 | $16.4M | $30.4M | — | OTX-2002 suspended |
The company's cumulative losses exceeded $200 million over 2022-2023 alone (approximately $102.7 million in 2022 and $97.4 million in 2023).
In March 2024, Omega laid off 35% of its workforce in an effort to extend its cash runway. The company implemented a strategic prioritization initiative during Q1 2024, focusing resources on certain programs while winding down others. Kaan Certel joined as Chief Business Officer in May 2024, bringing experience from BioCity Biopharma and Sanofi's Global Oncology External Innovation group. Despite these measures, Omega warned investors it had only enough capital to fund operations into the second quarter of 2025. In November 2024, the company suspended its clinical asset OTX-2002, and the Board appointed Certel as CEO, succeeding Mahesh Karande.
The proximate cause of bankruptcy was a January 2025 liquidity crisis triggered by the company's prepetition lender:
| Date | Event | Impact |
|---|
| Prior to January 2025 | Secured credit facility with Banc of California | Operating under loan covenants |
| January 13, 2025 | BOC swept $14,666,666.72 from accounts | Immediate liquidity crisis |
| January 17, 2025 | BOC issued notice of default | Claimed material adverse changes |
| January 29, 2025 | BOC released liens, terminated agreement | Relationship severed |
| February 3, 2025 | RSA executed with Pioneering Medicines | Bridge financing secured |
| February 10, 2025 | Chapter 11 petition filed | Less than $500K cash remaining |
The Debtor contested the default in the First Day Declaration, asserting it had not breached the loan agreement and had projected covenant compliance through April 2025. However, the cash sweep left the company with less than $500,000 in operating capital, limiting its ability to continue operations. The bank's January 29 release of liens and termination of the loan agreement formalized the relationship's end, leading the company to file for bankruptcy.
The sale proceeded under a Restructuring Support Agreement executed on February 3, 2025—seven days before filing—with Pioneering Medicines 08-B Inc., an affiliate of Flagship Pioneering. The RSA provided a $1.4 million secured promissory note (later increased to $1,475,178 plus $165,000 in fees) as bridge financing, with PM08-B committing to serve as both debtor-in-possession lender and stalking horse bidder.
Pioneering Medicines 08-B provided DIP financing to sustain operations through the sale process:
| Term | Detail |
|---|
| DIP Lender | Pioneering Medicines 08-B, Inc. |
| Total Facility | ~$10,359,677 |
| Structure | New money tranches + prepetition note roll-up |
| Interest Rate | 10% per annum |
| Interim Order | February 11, 2025 |
| Final Order | March 12, 2025 |
| DIP Counsel | Goodwin Procter LLP / Polsinelli PC (local) |
| Uses | Operations, professional fees, wind-down |
The DIP financing approval enabled the Debtor to maintain operations and fund the sale process through closing. The structure—prepetition bridge financing converted to DIP claims—is common in insider-controlled transactions and established Flagship's secured position at the top of the capital structure.
The Section 363 sale proceeded on an accelerated timeline:
| Date | Milestone |
|---|
| February 10, 2025 | Chapter 11 petition filed |
| February 11, 2025 | First Day Hearing; interim DIP approved |
| February 17, 2025 | Bidding Procedures Motion filed |
| February 20, 2025 | Official Committee of Unsecured Creditors appointed |
| March 12, 2025 | Final DIP Order; Bidding Procedures Order entered |
| March 19, 2025 | Schedules and Statement of Financial Affairs filed |
| March 21, 2025 | Section 341 Meeting of Creditors |
| April 1, 2025 | Bid deadline (extended) |
| April 4, 2025 | Auction cancelled; PM08-B designated successful bidder |
| April 23, 2025 | Sale hearing |
| April 25, 2025 | Sale Order entered |
Pioneering Medicines 08-B submitted a credit bid structured under Section 363(k) of the Bankruptcy Code:
| Component | Detail |
|---|
| Buyer | Pioneering Medicines 08-B, Inc. |
| Base Credit Bid | Not less than $11,461,086 |
| Additional Consideration | Assumption of certain liabilities |
| Cure Amounts | Payment of cure costs for assumed contracts |
| Total Approximate Value | ~$14 million |
Triple P Securities, LLC conducted the marketing process, but no competing bids emerged. The auction was cancelled on April 4, 2025, and PM08-B was designated as the successful bidder without competitive bidding. The court approved the sale on April 25, 2025—74 days from filing. The Sale Order included good faith findings under Section 363(m).
The sale transferred substantially all of Omega's assets to Pioneering Medicines 08-B:
Intellectual Property:
- OMEGA Epigenomic Programming platform
- OTX-2002 clinical program data and IP
- Patents and patent applications
- Regulatory designations (Orphan Drug, IND)
Contractual Rights:
- Novo Nordisk research collaboration (up to $532M potential value)
- Clinical supply agreements
- License agreements
Tangible and Other Assets:
- Laboratory equipment and office furniture
- Computer hardware and software
- Books, records, and clinical trial data
- Specified causes of action
- Insurance policies and proceeds
Following the sale closing, the case transitioned to plan confirmation. The Debtor filed its Combined Disclosure Statement and Plan on May 27, 2025, with the caption changed to OMGA Liquidating, Inc. on May 7, 2025 to reflect the wind-down posture. The Disclosure Statement was approved for solicitation on June 13, 2025, and the Plan Supplement was filed July 11, 2025.
| Date | Event |
|---|
| May 7, 2025 | Caption changed to OMGA Liquidating, Inc. |
| May 27, 2025 | Combined Disclosure Statement and Plan filed |
| June 13, 2025 | Disclosure Statement approved for solicitation |
| July 11, 2025 | Plan Supplement filed |
| July 28, 2025 | Memorandum in Support of Confirmation filed |
| July 30, 2025 | Confirmation Hearing |
| July 31, 2025 | Confirmation Order entered |
| August 8, 2025 | Plan Effective Date; Plan substantially consummated |
The Plan established the following treatment for claims:
| Class | Description | Treatment | Recovery |
|---|
| Administrative | Administrative claims | Paid in full | 100% (if allowed) |
| Priority | Priority tax and employee claims | Paid in full | 100% (if allowed) |
| Secured | Secured claims | Satisfied through sale | Per agreement |
| GUC | General unsecured claims | Pro rata from remaining assets | Minimal (TBD) |
| Equity | Equity interests | Cancelled | 0% |
Steven Balasiano was appointed as Plan Administrator with broad authority to manage the wind-down, resolve claims, and administer distributions. Cole Schotz P.C. serves as counsel to the Plan Administrator. As of December 2025, claims reconciliation remains active, with no distributions yet made to general unsecured creditors.
Approximately 140 claims were filed against the Debtor through established bar dates. The Plan Administrator has filed multiple omnibus objections to reduce and reconcile claims:
| Objection | Date Filed | Type |
|---|
| Second Omnibus | July 24-25, 2025 | Substantive |
| Third Omnibus | November 5, 2025 | Reduced Claim, No Liability |
| Fourth Omnibus | November 5, 2025 | Amended Claims, Equity Claims, Books & Records |
The Claims Objection Deadline was extended to May 5, 2026, reflecting the ongoing nature of claims reconciliation.
| Creditor | Claim Type | Amount |
|---|
| Massachusetts Department of Revenue | Priority/Taxes | $33,293 + $4,017 |
| Broadridge Financial | General Unsecured | $64,600 |
| Nasdaq, Inc. | General Unsecured | $2,046 |
| Lovelace Biomedical Research Institute | General Unsecured | $2,383 |
| Various Equity Holders | Equity Interest | Disallowed |
| Counterparty | Relationship | Disposition |
|---|
| Novo Nordisk A/S | Research collaboration | Assumed by Buyer |
| Roche/Hoffmann-La Roche | Clinical supply | — |
| Oracle America, Inc. | Technology vendor | Admin claim filed |
| Tempus AI, Inc. | Data/analytics | Reservation of rights |
| AWS (Amazon Web Services) | Cloud computing | Assumption addressed |
| Alexandria Real Estate | Life sciences landlord | On creditor matrix |
Post-confirmation, the Plan Administrator authorized rejection of certain unexpired leases, including a copier lease, nunc pro tunc to July 31, 2025.
Omega's workforce reductions occurred in two distinct phases reflecting the company's financial position. The March 2024 layoff eliminated 35% of employees as the company sought to extend its cash runway following the Novo Nordisk partnership announcement.
Following the bankruptcy filing, the court approved termination of approximately 17 additional employees, effective immediately. A key employee retention program was implemented for one employee identified as necessary to the sale process. Only minimal staff remained to support asset preservation and wind-down activities.
Employee priority claims for wages and benefits were addressed through the Plan, with the Plan Administrator continuing to reconcile allowed priority claims.
Professional fees across debtor and committee counsel, financial advisors, and claims administration consumed a portion of available proceeds:
| Firm | Role | Estimated Fees |
|---|
| Debtor Professionals | | |
| Morris, Nichols, Arsht & Tunnell LLP | Bankruptcy Counsel | ~$2,000,000+ |
| Triple P RTS, LLC / Triple P Securities | Restructuring/Investment Banker | ~$842,000+ |
| Kroll Restructuring Administration LLC | Claims Agent | ~$75,000+ |
| Ernst & Young LLP | Ordinary Course Professional | — |
| Foley Hoag LLP | Ordinary Course Professional | — |
| Committee Professionals | | |
| Cole Schotz P.C. | UCC Counsel | ~$466,000+ |
| Dundon Advisers LLC | UCC Financial Advisor | ~$119,000+ |
Total professional fees exceeded $3.5 million, representing approximately 25% of the total sale value of roughly $14 million. Final fee applications were processed in October 2025, with an Omnibus Fee Order entered covering all professionals.
Flagship Pioneering maintained control at every stage of Omega's restructuring:
| Phase | Flagship Position |
|---|
| Pre-petition | 53% equity ownership as largest shareholder |
| Bridge Loan | $1.4M prepetition secured note through PM08-B |
| DIP Lender | ~$10.4M facility through PM08-B |
| Stalking Horse | Credit bid acquisition through PM08-B |
| Result | Assets transferred to Flagship affiliate without competitive bidding |
The credit bid structure under Section 363(k) of the Bankruptcy Code allowed PM08-B to bid the value of its DIP and prepetition loans without providing additional cash. Potential third-party bidders must raise and deploy cash, while the secured lender can forgive debt in exchange for assets.
The Official Committee of Unsecured Creditors was appointed February 20, 2025 and actively participated throughout the case, engaging Cole Schotz P.C. as counsel and Dundon Advisers LLC as financial advisor to provide analysis of transaction terms. Triple P Securities conducted outreach to potential acquirers as investment banker. The sale included protections against reversal on appeal.
Industry Context: Biotech Bankruptcy Trends
Omega's chapter 11 filing occurred amid a sustained wave of biotechnology bankruptcies. In 2024, 13 biotech firms filed for bankruptcy—just one less than the 10-year high of 14 in 2023. Of the 2024 filings, six companies reorganized while seven liquidated. This pattern continued into 2025, with Omega among the early filings.
The epigenetic drugs market is estimated at $8.50 billion in 2025 in North America, projected to reach $42.38 billion by 2034 at a 19.54% CAGR. DNA methylation technologies dominate with 41.4% market share.
Post-Confirmation Status
As of December 2025, the case remains active in wind-down:
| Milestone | Status |
|---|
| Plan Effective Date | August 8, 2025 |
| Sale Closed | Completed |
| Wind-Down | Ongoing |
| Claims Reconciliation | Active |
| Distributions | Pending final claims resolution |
| Next Hearing | December 17, 2025 |
The Q3 2025 Post-Confirmation Report filed October 21, 2025 indicated no distributions had yet been made. Claims reconciliation continues, with the Third and Fourth Omnibus Objections pending at the December 17, 2025 hearing. The claims objection deadline extension to May 5, 2026 leaves final distributions pending.
The Plan Administrator continues to manage the wind-down, process claim objections, and prepare for eventual distributions. Equity claims filed by shareholders are being disallowed pursuant to the Plan, which cancelled all equity interests without recovery.
Why did Omega Therapeutics file for bankruptcy?
The proximate cause was a January 2025 cash sweep by Banc of California, which seized $14.7 million from the company's accounts and left Omega unable to continue operations. Underlying factors included persistent quarterly losses ($16-20 million per quarter in 2024), limited upfront revenue from the Novo Nordisk partnership, and inability to secure alternative financing after suspending clinical development in November 2024.
What happened to the Novo Nordisk partnership?
The research collaboration was transferred to Pioneering Medicines 08-B as part of the Section 363 sale. The potential value of up to $532 million in milestones and royalties remains contingent on future development progress.
Who bought Omega's assets?
Pioneering Medicines 08-B, Inc., an affiliate of Flagship Pioneering (Omega's 53% shareholder), acquired substantially all assets through an approximately $14 million credit bid. No competing bidders emerged at the April 2025 auction despite marketing efforts.
What will general unsecured creditors recover?
The Plan provides for pro rata distributions to general unsecured creditors from remaining assets after administrative and priority claims are paid. With approximately $14 million in sale proceeds and over $3.5 million in professional fees, the amount available for distribution depends on remaining assets.
What happened to employees?
Omega reduced its workforce by 35% in March 2024 as a cost-cutting measure. Following the bankruptcy filing, approximately 17 additional employees were terminated, leaving minimal staff to support asset preservation and the sale process. Employee priority claims for wages and benefits are being addressed through the Plan.
Is the OTX-2002 clinical program continuing?
OTX-2002 was suspended in November 2024 before the bankruptcy filing, after Phase 1 completion with a 50% disease control rate in HCC patients. The program retains its Orphan Drug Designation and IND clearance.
Why were there no competing bids at auction?
Despite marketing efforts by Triple P Securities, no qualified competing bidders emerged.
How long did the bankruptcy case take?
The case moved in 74 days from filing to Sale Order (April 25, 2025) and 179 days from filing to Plan Effective Date (August 8, 2025). Claims reconciliation continues into 2026, with the claims objection deadline extended to May 5, 2026.
What is the current status of the case?
As of December 2025, the Plan Administrator is reconciling the approximately 140 claims filed. The Third and Fourth Omnibus Objections are pending at a December 17, 2025 hearing. No distributions have been made. The company has been renamed OMGA Liquidating, Inc.
What was Omega's IPO valuation compared to the sale price?
Omega priced its July 2021 IPO at $17.00 per share, valuing the company at approximately $866 million. The bankruptcy sale closed at approximately $14 million via credit bid—less than 2% of the IPO valuation.
For more insights on bankruptcy trends across industries, visit the ElevenFlo bankruptcy blog.
